NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Dr. Matthew Sherman
Acceleron Pharma Announces Executive Appointments and Promotions
Acceleron Pharma, a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic candidates that regulate cellular growth and repair, has made two executive promotions and appointments from within the organization. Steven Ertel has been named executive VP and chief operating officer; he previously held the title of senior VP and chief business officer. In addition, Matthew Sherman, M.D., has been promoted to executive VP and chief medical officer. Dr. Sherman joined Acceleron in 2006 and immediately made key contributions such as recognizing sotatercept as a potential treatment for anemia.
Cerulean Appoints President and CEO
Cerulean Pharma, which uses its dynamic tumor targeting platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations, has named Christopher Guiffre, president and CEO. Mr. Guiffre has served as Cerulean’s chief operating officer since 2014.
BIND Therapeutics Announces Management Changes
BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, has named Andrew Hirsch as acting president and CEO.
Mr. Hirsch was formerly BIND’s chief operating officer and chief financial officer.
He replaces Scott Minick, who remains a member of BIND’s board of directors.
BIND intends to announce a permanent CEO shortly.
Mersana Appoints President and CEO
Mersana, which engineers antibody-drug conjugates (ADCs) that maximize the potential of new and established therapeutic classes, has named Anna Protopapas as president and CEO. Ms. Protopapas was most recently president of Millennium Pharmaceuticals.
Dr. Benjamin Yerxa
Envisia Therapeutics Names President
Envisia Therapeutics has named Benjamin Yerxa, Ph.D., as the president. Dr. Yerxa joined Liquidia Technologies in August 2012 and was critical to the company’s formation of Envisia in November 2013 where he has since served in the dual role of chief scientific officer for both companies.
SynteractHCR Expands Senior Management Team
SynteractHCR, a full-service, international CRO, has hired Etienne Drouet as VP, strategic development. This is a new position created to augment the depth of the company’s oncology and complex trial expertise.
Mr. Drouet joins SynteractHCR from Premier Research where he was executive director, global oncology.
Quintiles Names President, Advisory Services
Quintiles has appointed Elgar Peerschke to serve as president, advisory services. In this role, Mr. Peerschke is responsible for the continued development and delivery of its related services. Bringing more than 25 years of experience to Quintiles, Mr. Peerschke joins Quintiles from Bain & Company, a global business consulting firm, where he was a senior partner in its global healthcare practice group and a leading client service partner.
Dr. Tim Gustafson
Apervita Expands Management Team
Apervita, a health analytics community, has appointed Tim Gustafson, M.D., as chief content officer. In his role, Dr. Gustafson is responsible for leading Apervita’s author community and oversees the growth of content offered on Apervita’s market for health analytics, including algorithms, measures, pathways, protocols, and data focused on critical health areas, such as chronic disease management, preventable adverse events, readmissions, cancer, early warning, quality, and safety.
Before joining Apervita, Dr. Gustafson spent 10 years as a health strategy and innovation consultant as a principal and expert principal at Innosight, a global innovation firm.
Veeva Names Executive VP, Global Sales
Veeva Systems has hired Alan Mateo as executive VP of global sales. Mr. Mateo is charged with leading Veeva’s worldwide salesforce and reports to Veeva’s Co-founder and CEO Peter Gassner.
Mr. Mateo brings more than 30 years of experience in enterprise software. He spent the last 10 years selling clinical cloud solutions in life sciences while head of worldwide field operations at Medidata Solutions.
Dr. Colleen McHorney
ERT Expands Scientific Consulting Group
ERT, a global solution provider for high-quality patient safety and efficacy endpoint data collection, has expanded its cardiac safety, respiratory, and clinical outcome assessment (COA)/electronic COA (eCOA) consulting group with the addition of Colleen McHorney, Ph.D., as senior scientist in its COA consulting group. With 30 years of experience, Dr. McHorney’s expertise spans from qualitative research for concept elicitation and patient comprehension to advanced classical and modern psychometric techniques for item analysis and scale validation. (PV)
For bonus content go to bit.ly/PV0515-Pool